Grünenthal On Hunt For Asia Partner As Pain Killer Hits Phase III Endpoints
Executive Summary
Grünenthal’s novel pain killer has succeeded in a Phase III trial in cancer pain and now the company wants to find a partner for Asian markets, to complement its deal last year with Depomed for North America.
You may also be interested in...
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Antibe Speeds Hydrogen Sulfide-Releasing NSAID Development
Canada’s Antibe Therapeutics is accelerating the early-stage clinical development of new molecules that depend on the cytoprotective and signaling properties of minute amounts of hydrogen sulfide to have a potent anti-inflammatory and analgesic effect.
10 US Approval Decisions To Look Out For In Q3
This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.